1. 厚⽣労働省「平成 29 年 全国がん登録罹患数・罹患率 報告」 https://www.mhlw.go.jp/content/10900000/000624853.pdf (最終アクセス 2021 年 3 ⽉ 29 ⽇)
2. 国⽴がん研究センターがん情報サービス「 がん登録・統計 」 https://ganjoho.jp/reg_stat/statistics/stat/index.html (最終アクセス 2021 年 3 ⽉ 29 日)
3. ⽇本乳癌学会: 乳癌診療ガイドライン2疫学・診断編 2018 年版, ⾦原出版株式会社. 東京, 2018;28-30,43-45
4. 厚⽣労働省: 平成 28 年「国⺠健康・栄養調査」の結果 https://www.mhlw.go.jp/stf/houdou/0000177189.html (最終アクセス 2021 年 3 ⽉ 21 ⽇)
5. 中村⼆郎、神⾕英紀、⽻⽥勝計、稲垣暢也、⾕澤幸⽣、荒⽊栄⼀、植⽊浩⼆郎、中⼭健夫: ―糖尿病の死因に関する委員会報告―アンケート調査による⽇本⼈糖尿病の死因―2001~2010 年の 10 年間、 45,708 名での検討―. 糖尿病 2016;59(9):667-684
6. Ido W, Siegal S, Raphael C, Avraham K, Bella K: Diabetes mellitus and breast cancer Lancet Oncology 2005;6: 103‒11
7. Larsson SC, Mantzoros CS, Wolk A: Diabetes mellitus and risk of breast cancer: A meta-analysis. International Journal of Cancer 2007;121:856‒862
8. Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, Fairley L. L, Boniol M, Zheng T, Zhang Y, Pasterk M, Smans M, Curado M. P, Mullie P, Gandini S, Bota M, Bolli G. B, Rosenstock J, Autier P: Diabetes and breast cancer risk: a meta-analysis. British Journal of Cancer 2012;107:1608‒1617
9. Zhao XB, Ren, G: Diabetes mellitus and prognosis in women with breast cancer. Medicine 2016;95:49:e5602
10. Schrauder M G, Fasching P A, Häberle L, Lux M P. Rauh C, Hein A, Bayer C M, Heusinger K, Hartmann A, Strehl J D, Wachter D L, Schulz-Wendtland R, Adamietz B, Beckmann, Matthias W. Loehberg, Christian R: Diabetes and prognosis in a breast cancer cohort Journal of Cancer Research and Clinical Oncology 2011;137:975‒983
11. Erickson K, Patterson R E, Flatt S W, Natarajan L, Parker B A, Heath D D, Laughlin G A, Saquib N, Rock Cl L, Pierce J P: Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. Journal of Clinical Oncology 2011;29:1, 54-60
12. Kang. C, Leroith. D, Gallagher. E: Diabetes, Obesity, and Breast Cancer. Endocrinology 2018;159(11):3801-3812
13. Seino Y, Yabe D: Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. Journal of Diabetes Investigation 2013;4:2:108-130
14. Ahrén B, Schmitz O: GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004;36(11-12):867-76
15. Seino Y, Yabe D: Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and β cell preservation. Progress in Biophysics and Molecular Biology 2011;107:248e256
16. Kaku K, Rasmussen M F, Nishida T, Seino Y: Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes. Journal of Diabetes Investigation 2011;2:441-447
17. Inagaki N, Ueki K, Yamamura A, Saito H, Imaoka T: Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes. J Diabetes Investig. 2011;2:448-456
18. Committee for Medicinal Products for Human Use, European Medicines Agency (2015) Assessment report Saxenda International non-proprietary name: liraglutide https://www.ema.europa.eu/en/documents/assessment-report/saxenda-eparpublic-assessment-report_en.pdf (最終アクセス 2021 年 3 ⽉ 21 ⽇)
19. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau D C.W, le Roux C W, Violante O R, Jensen C B, Wilding J P.H: A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine 2015;373:1:11-22
20. Elashoff M, Matveyenko A V, Gier, B, Elashoff R, Butler P C: Pancreatitis, pancreatic, and thyroid cancer with Glucagon-like peptide-1 based therapies. Gastroenterology 2011;141:150‒156
21. Koehler J A, Baggio L L, Yusta B, Longuet C, Rowland, Katherine J, Cao Xiemin, Holland Dianne, Brubaker Patricia L, Drucker Daniel J: GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7. Cell Metabolism 2015;21:379-391
22. Hicks B M, Yin H, Yu O H.Y, Pollak M N, Platt R W, Azoulay L: Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: Population based cohort study using the UK Clinical Practice Research Datalink. BMJ (Online) 2016;355:1-8
23. ⽇本糖尿病学会: 糖尿病診療ガイドライン 2019 南江堂, 東京, 2019; 5-6
24. Goldhirsch A, Wood W. C, Coates A. S, Gelber R. D, Thürlimann B, Senn H. J: Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Annals of Oncology 2011;22:1736‒1747
25. Song Y, Zhou M, Cao Y, Qi J, Geng J, Liu X: Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine. Oncology Letters 2017;13: 2684-2690
26. Sun S, Jiang Y, Zhang G, Song H, Zhang X, Zhang Y, Liang X, Sun Q, Pang D: Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer Journal of Surgical Oncology 2012;105:773‒779
27. Fan E W, Li C-C, Wu W-J, Huang C-N, Li W-M, Ke H-L, Yeh H-C, Wu T-F, Liang P-I, Ma L-J, Li C-F: FGF7 Over Expression is an Independent Prognosticator in Patients with Urothelial Carcinoma of the Upper Urinary Tract and Bladder. THE JOURNAL OF UROLOGY 2015;194:223-229
28. Calanna S, Christensen M, Holst J. J, Laferrère B, Gluud L L, Vilsbøll T, Knop F. K: Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: Systematic review and meta-analyses of clinical studies. Diabetologia 2013;56(5): 965‒972
29. Yamaoka T M, Tojo T, Takahira N, Matsunaga A, Aoyama N, Masuda T, Izumi T: Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovascular Diabetology 2010;9:17:1-9
30. Kanda R, Hiraike H, Wada-Hiraike O, Ichinose T, Nagasaka K, Sasajima Y, Ryo E, Fujii T, Osuga Y, Ayabe T: Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer. BMC Cancer Jun 2018;15;18(1):657
31. Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B, Rubinek T: The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res Treat. 2012 Apr;132(2):449-61
32. Zhao H, Wei R, Wang, Tian Q, Tao M, Ke J, Liu Y, Hou W, Zhang L, Yang J, Hong T: Activation of glucagon-like peptilde-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. Am J Physiol Endocrinol Metab 2014;306: E1431-E1441
33. Palmieri C, Roberts-Clark D, Assadi-Sabet A, Coope R. C, O'Hare M, Sunters, A, Hanby A, Slade M. J, Gomm J. J, Lam E. W.F., Coombes R. C: Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1 -induced paracrine growth factor for human breast cells. J Endocrinol 2003;77:65-81
34. Tannheimer S. L, Rehemtulla A, Ethier S. P: Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2000;2:311-20
35. Lei H, Deng C X Haipeng Lei and Chu-Xia Deng: Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer. International Journal of Biological Sciences 2017;13(9): 1163-1171
36. Kim S, Dubrovska A, Salamone RJ, Walker JR, Grandinetti KB, Bonamy GM, Orth AP, Elliott J, Porta DG, Garcia-Echeverria C, Reddy VA: FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells. PLoS ONE 2013;8(1):e51671
37. Cui F, Wu D, Wang W, He X, Wang M: Variants of FGFR2 and their associations with breast cancer risk: a HUGE systematic review and meta-analysis. Breast Cancer Research and Treatment 2016;155:313-35
38. Zang X P, Pento J T: Keratinocyte growth factor-induced motility of breast cancer cells. Clin Exp Metastasis 2000;18(7):573-80
39. Wu XY, Xu H, Wu ZF, Chen C, Liu JY, Wu GN, Yao XQ, Liu FK, Li G, Shen L: Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Oncotarget Dec 2015;29;6(42):44563-78
40. Eiro N, Cid S, Fraile M, Cabrera JR, Gonzalez LO, Vizoso FJ: Analysis of the Gene Expression Profile of Stromal Pro-Tumor Factors in Cancer-Associated Fibroblasts from Luminal Breast Carcinomas. Diagnostics (Basel) 2020;Oct 23;10(11):865
41. Michels K B, Solomon C G, Hu F B, Rosner B A, Hankinson S E, Colditz G A, Manson J E: Type 2 diabetes and subsequent incidence of breast cancer in the nurses' health study. Diabetes Care 2003;26:6: 1752-1758
42. Turczyk L, Kitowska K, Mieszkowska M, Mieczkowski K, Czaplinska D, Piasecka D, Kordek R, Skladanowski A C, Potemski P, Romanska H M, Sadej R: FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells. Neoplasia 2017;19 791‒804
43. Pyke C, Heller R. S, Kirk R K, Ørskov C, Reedtz-R S, Kaastrup P, Hvelplund A, Bardram L, Calatayud D, Knudsen L B: GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014;155(4):1280‒1290